Blood News and Research

RSS

Study finds that triple therapy corrects two core defects in type 2 diabetes

Patients with type 2 diabetes fare significantly better if they are started on three medications at the time of diagnosis than if they are prescribed a single drug and have other therapies added later, a San Antonio researcher said June 22 at the 73rd Scientific Sessions of the American Diabetes Association in Chicago.

25 Jun 2013

Melody Transcatheter Pulmonary Valve brings new hope to congenital heart patients

Many adult congenital heart patients have undergone multiple heart surgeries by the time they reach their 20s. Each time surgeons operate on the heart, the risk of complications increases.

25 Jun 2013

Thermo Fisher Scientific and Newman-Lakka Institute collaborate to develop new diagnostic approaches for personalized cancer treatment

Thermo Fisher Scientific Inc., the world leader in serving science, and the Newman-Lakka Institute for Personalized Cancer Care at Floating Hospital for Children at Tufts Medical Center, announced an intended collaboration for research and development of new methods to detect and track circulating biomarkers in blood.

25 Jun 2013

Study finds decrease in risk of death from ischemic stroke in US black children

The excess risk of death from ischemic (due to reduced blood flow), but not hemorrhagic (due to bleeding), stroke in US black children has decreased over the past decade, according to a study by Laura L. Lehman, M.D., of Boston Children's Hospital, and colleagues.

25 Jun 2013

Study examines long-term effects on babies born to mothers with obstetric cholestasis

Babies born to mothers who suffer from a rare metabolic complication during pregnancy are programmed to be overweight, according to a study published today in the Journal of Clinical Investigation.

25 Jun 2013

Weight loss does not reduce heart disease risks among Type 2 diabetes patients: Study

A landmark study investigating the long-term effects of weight loss on the risks of cardiovascular disease among patients with Type 2 diabetes has now concluded, with significant results to be published today in the New England Journal of Medicine.

25 Jun 2013

New study provides guidelines for stem cell transplantation in older MDS patients

A new study by an international team led by Dana-Farber Cancer Institute scientists provides the first statistically-based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes - the most common blood disorders in people over 60 years of age, and frequently a precursor for leukemia.

25 Jun 2013

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers.

25 Jun 2013

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Elcelyx Therapeutics announced today that clinical study results confirm that the primary site of action of Type 2 diabetes medicine metformin is in the lower bowel rather than in the circulation.

24 Jun 2013

New method allows assessment of direct stimulation effects on electric activity of human brain

Neuroscientists at the University of Tübingen have become the first to record neuromagnetic activity in the millisecond-by-millisecond range while the brain of a human subject was under stimulation by electric current. Electric brain stimulation has successfully been used in the treatment of neurological and psychiatric disorders for many decades.

24 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that comprehensive data from a study of the company's PaQ Insulin Delivery Device will be presented today and tomorrow at the American Diabetes Association 73rd Scientific Sessions in Chicago, IL. The data suggest that PaQ can reduce known barriers to insulin therapy among people with type 2 diabetes, potentially improving their glycemic control.

24 Jun 2013

Researchers provide new revelations about intricate pathways involved in turning on T cells

A major study from researchers at the La Jolla Institute for Allergy and Immunology provides new revelations about the intricate pathways involved in turning on T cells, the body's most important disease-fighting cells, and was published today in the prestigious scientific journal Nature.

24 Jun 2013

Administering large iron doses over short period of time increases patients' risk of infections

While intravenous iron is critical for maintaining the health of many dialysis patients, administering large doses over a short period of time increases patients' risk of developing serious infections, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Smaller doses given for a longer period of time appears to be much safer.

24 Jun 2013

Joslin Diabetes Center, Sanofi US present results from multicultural outreach program

Sanofi US collaborated with Joslin Diabetes Center on a successful, multicultural outreach pilot that was overseen and funded by Sanofi US with Joslin as its partner in providing clinical and behavioral educational materials and training based on their award-winning On the Road diabetes program.

24 Jun 2013

Research shows other viruses also play a role in AIDS transmission

While antiretroviral drugs offer an efficient means of preventing the replication of HIV in the blood, shedding of HIV may occur in semen, so that other persons can become infected during unprotected sexual intercourse.

24 Jun 2013

New $11 million grant for lowering stroke risk among black and young populations

A new $11 million grant to Kaiser Permanente Northern California and UC San Francisco will support a multifaceted research program aimed at lowering stroke risk among black populations and younger stroke victims by targeting high blood pressure, also known as hypertension.

21 Jun 2013

Blood News and Research

Study finds that triple therapy corrects two core defects in type 2 diabetes

Melody Transcatheter Pulmonary Valve brings new hope to congenital heart patients

Thermo Fisher Scientific and Newman-Lakka Institute collaborate to develop new diagnostic approaches for personalized cancer treatment

Study finds decrease in risk of death from ischemic stroke in US black children

Study examines long-term effects on babies born to mothers with obstetric cholestasis

Weight loss does not reduce heart disease risks among Type 2 diabetes patients: Study

New study provides guidelines for stem cell transplantation in older MDS patients

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

New method allows assessment of direct stimulation effects on electric activity of human brain

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

Researchers provide new revelations about intricate pathways involved in turning on T cells

Administering large iron doses over short period of time increases patients' risk of infections

Joslin Diabetes Center, Sanofi US present results from multicultural outreach program

Research shows other viruses also play a role in AIDS transmission

New $11 million grant for lowering stroke risk among black and young populations

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News